Japanese regulatory authority's perspective on biosimilars reply

被引：0

作者：

Bennett, Charles L. ^{[1
,2
,3
,4
,5
]}

Chen, Brian ^{[1
,2
,5
]}

Hermanson, Terhi ^{[6
]}

Georgantopoulos, Peter ^{[1
,2
,3
,5
]}

Sartor, Oliver A. ^{[7
]}

机构：

[1] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA

[2] Univ S Carolina, South Carolina Coll Pharm, SONAR, Columbia, SC 29208 USA

[3] WJB Dorn VA Med Ctr, Columbia, SC USA

[4] Hollings Canc Ctr, Charleston, SC USA

[5] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA

[6] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland

[7] Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70118 USA

来源：

LANCET ONCOLOGY | 2015年 / 16卷 / 03期

关键词：

FOLLOW-ON BIOLOGICS;

D O I：

10.1016/S1470-2045(15)70047-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E102 / E102

页数：1

共 50 条

[1] Japanese regulatory authority's perspective on biosimilars
Nagai, Sumimasa
Yanagihara, Reiko
Kishioka, Yasuhiro
[J]. LANCET ONCOLOGY, 2015, 16 (03): : E101 - E101
[2] Health authority perspective on biosimilars
Godman, Brian
[J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (01): : 10 - 11
[3] Iraqi regulatory authority current system and experience with biosimilars
Al-Kinani, Khalid K.
Ibrahim, Mazin J.
Al-Zubaidi, Ruaa F.
Younus, Manal M.
Ramadhan, Samir H.
Kadhim, Hussein J.
Challand, Rodeina
[J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 117
[4] Biosimilars: a regulatory perspective from America
Kay, Jonathan
[J]. ARTHRITIS RESEARCH & THERAPY, 2011, 13 (03)
[5] Biosimilars: a regulatory perspective from America
Jonathan Kay
[J]. Arthritis Research & Therapy, 13
[6] Current Japanese Regulatory Systems for Generics and Biosimilars
Kuribayashi, Ryosuke
Sawanobori, Kenji
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (03) : 785 - 787
[7] Challenges for Streamlining the Development of Biosimilars: A Japanese Perspective
Arato, Teruyo
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 30 - 36
[8] Safety assessment of biosimilars in Europe: a regulatory perspective
Giezen, Thijs J.
Schneider, Christian K.
[J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2014, 3 (04): : 180 - 183
[9] REGULATORY IMPLICATIONS - AN AUTHORITY PERSPECTIVE
CARTWRIGHT, AC
[J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1991, 19 (02) : 465 - 467
[10] Regulatory toxicology from an authority perspective
Kass, G. E.
[J]. TOXICOLOGY LETTERS, 2022, 368 : S3 - S3

← 1 2 3 4 5 →